title: Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function.
abstract: Knockout mutants of Plasmodium falciparum lacking pfpm1, pfpm2 and pfhap (triple-PM KO), and mutants lacking all four digestive vacuole (DV) plasmepsins (pfpm4, pfpm1, pfpm2 and pfhap; quadruple-PM KO), were prepared by double cross-over integration effecting chromosomal deletions of up to 14.6 kb. The triple-PM KO was similar to the parental line (3D7) in growth rate, morphology and sensitivity to proteinase inhibitors. The quadruple-PM KO showed a significantly slower rate of growth in standard medium, which manifested as delayed schizont maturation accompanied by reduced formation of haemozoin. In amino acid-limited medium, the reduction in growth rate of the quadruple-PM KO was pronounced. The sensitivity of both the triple- and quadruple-PM KOs to six different HIV aspartic proteinase inhibitors was comparable to that of 3D7, thus establishing that the DV plasmepsins were not the primary targets of the antimalarial activity of these clinically important compounds. Electron microscopic analysis revealed the presence of multilamellar bodies resembling ceroid in the DV of the quadruple-PM KO, and intermediates of the autophagic pathway accumulated as determined by Western blot analysis. Thus, the DV plasmepsins, although not essential, contribute significantly to the fitness of the parasite and are required for efficient degradation of endosomal vesicles delivered to the DV.
authors.affiliation: Department of Infectious Diseases and Pathology, University of Florida, Gainesville, FL 32611, USA.
authors.forename: J Alfredo
authors.initials: JA
authors.lastname: Bonilla
authors.forename: Tonya D
authors.initials: TD
authors.lastname: Bonilla
authors.forename: Charles A
authors.initials: CA
authors.lastname: Yowell
authors.forename: Hisashi
authors.initials: H
authors.lastname: Fujioka
authors.forename: John B
authors.initials: JB
authors.lastname: Dame
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000494:pharmacology; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D004912:Erythrocytes / Q000378:metabolism / Q000469:parasitology; D017353:Gene Deletion; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D008854:Microscopy, Electron; D021261:Parasitic Sensitivity Tests; D010963:Plasmodium falciparum / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics / Q000254:growth & development / Q000648:ultrastructure; D015800:Protozoan Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D014617:Vacuoles / Q000201:enzymology* / Q000378:metabolism
chemical_list: D000962:Antimalarials; D017320:HIV Protease Inhibitors; D015800:Protozoan Proteins; D016282:Aspartic Acid Endopeptidases; C089643:plasmepsin